Lifecore Biomedical (NASDAQ:LFCR) Posts Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Key Points

• Q1 miss and weak results: Lifecore reported ($0.43) EPS vs. consensus ($0.24) (a $0.19 miss), revenue down 34% YoY to $23.2M, a $15M net loss and only $1M adjusted EBITDA, reflecting front‑loaded headwinds and timing shifts.
• Management reaffirmed targets and secured commercial wins: The company reiterated 2026 guidance of $120–125M revenue and $20.5–25M adjusted EBITDA with a goal of 12% CAGR and >25% EBITDA margin by 2029, and signed three site‑transfer/CDMO agreements expected to be commercial by 2028.
• Cost cuts, stronger liquidity and operational progress: SG&A and R&D have been cut by nearly $8M since late‑2024, the company reported its fifth consecutive quarter of positive operating cash flow and ended Q1 with roughly $38M in liquidity while reporting smooth ERP implementation and positive customer inspections.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.19), FiscalAI reports. The company had revenue of $23.19 million during the quarter, compared to analyst estimates of $25.96 million. Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%.

Here are the key takeaways from Lifecore Biomedical's conference call:

• Reaffirmed 2026 guidance and mid‑term targets — Lifecore reiterated 2026 revenue guidance of $120–125M and adjusted EBITDA of $20.5–25M, and reiterated a goal of 12% revenue CAGR and >25% EBITDA margin by end of 2029.
• Q1 results disappointed — revenue fell 34% year‑over‑year to $23.2M, gross profit declined and the company reported a $15M net loss with adjusted EBITDA of $1M, driven by front‑loaded headwinds and timing shifts.
• Notable business development wins — signed three commercial site‑transfer/CDMO agreements (including an aesthetics onshore transfer and two programs with a U.S. biopharma customer) and expanded a late‑stage pipeline, with these transfers expected to be commercial by 2028 and represent mid‑seven‑figure opportunities each.
• Expense cuts and stronger liquidity — SG&A and R&D reduced by nearly $8M since late‑2024, fifth consecutive quarter of positive operating cash flow, and ending Q1 liquidity of ~ $38M (~$21M cash + ~$17M revolver availability).
• Operational and quality progress — ERP implementation went smoothly in January, multiple customer inspections had positive outcomes, and the company is preparing to support a planned doubling of its largest customer's commercial demand beginning in 2027.

Lifecore Biomedical Trading Down 3.9%

LFCR stock traded down $0.20 during midday trading on Wednesday, hitting $4.96. 221,757 shares of the company's stock were exchanged, compared to its average volume of 270,751. The business has a 50-day simple moving average of $5.29 and a two-hundred day simple moving average of $6.83. The stock has a market capitalization of $185.90 million, a PE ratio of -5.06 and a beta of 1.08. Lifecore Biomedical has a 1-year low of $3.63 and a 1-year high of $8.98.

Analyst Ratings Changes

Several research firms have issued reports on LFCR. Weiss Ratings reissued a "sell (d)" rating on shares of Lifecore Biomedical in a research note on Tuesday, April 21st. Barrington Research raised their target price on Lifecore Biomedical from $5.50 to $6.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $6.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers boosted its position in shares of Lifecore Biomedical by 54.0% during the second quarter. Rhumbline Advisers now owns 38,091 shares of the company's stock worth $309,000 after buying an additional 13,361 shares during the period. Wells Fargo & Company MN boosted its position in shares of Lifecore Biomedical by 69.7% during the fourth quarter. Wells Fargo & Company MN now owns 30,757 shares of the company's stock worth $252,000 after buying an additional 12,632 shares during the period. Boothbay Fund Management LLC purchased a new position in shares of Lifecore Biomedical during the third quarter worth $221,000. PharVision Advisers LLC purchased a new position in shares of Lifecore Biomedical during the third quarter worth $151,000. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Lifecore Biomedical by 20.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company's stock worth $137,000 after buying an additional 2,826 shares during the period. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.